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Pellucid zone 3 (ZP3) involves in fertilization mechanism. Moreover, an antibody of ZP3 can develop to inhibit egg 
and sperm interaction. This study aims to determine the effect of hZP3 (mab-hZP3) monoclonal antibody on the 
expression of Bcl-2 and Bax in follicle granulosa cells of the mice ovary. Female BALB/c mice were divided into 12 
groups which consisted of a control and experimental treatment group. Each group was added with 30% of total 
mice as error sample (1 mice). Each group was treated differently: 50 µL adjuvant Al(OH)3 in 50 µL Tris HCl, 20 
µg Mab-hZP3, 40 µg Mab- hZP3, and 60 µg Mab-hZP3. Each group was then dissected at day 10, 15 and 20. 
Measurement of Bcl-2 and Bax was performed with immunohistochemistry. Data were then analyzed by Two-Way 
ANOVA. The result showed that there was no significant effect of Mab-hZP3 administration in various doses on 
Bcl-2 (p = 0.0825), and Bax (p = 0.836). There was no significant effect of administration of Mab-hZP3 in time (p = 
0.807) on Bcl-2 expression (p = 0.088) but the significance difference was found in Bax level (p = 0.031). The lowest 
Bcl-2 level was found in a dose of 60 µg in day 15. There was no significant effect of Mab-hZP3 in various doses 
and time (p = 0.691), neither to Bcl-2 and Bax. The results obtained due to the specificity of a monoclonal antibody 
that recognizes a specific antigen. Mab-hZP3 is proposed as immunocontraception for women causing no disturb-
ance of folliculogenesis. 
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INTRODUCTION 
Contraception is required to control population’s 
growth rate which increased gradually each year, mostly 
in developing countries. However, hormonal contracep-
tion that commonly used causes side effects both tem-
porarily and permanently [1]. For that matter, contra-
ception is required to be safe, reliable, effective, and re-
versible to reduce side effects, one of which is immuno-
contraception [2]. 
Immunocontraception is a candidate derived from 
pellucid zone inhibiting the interaction between sperm 
and eggs, and it is currently being developed. Pellucid 
zone 3 (ZP3) involves in fertilization control.  Therefore, 
administration of ZP3 antibody can inhibit the interac- 
tion between sperm and eggs [3]. Aulanni’am and Su-
mitro found that ZP3 antibody was an effective inhibit-
ing interaction between sperm and eggs in vivo fertiliza-
tion by disrupting ZP3 binding to its ligand [4]. ZP3-
antibody based-contraception is also permanent and re-
versible [5]. However, studies regarding its side effects 
remain elusive. 
A side effect of immunocontraception on folliculo-
genesis remains controversial. Study of Calongos et al., 
using ovary follicle of mice with administration of ZP3 
antibody, showed smaller follicles and antrum, and it is 
also found in follicle culture with ZP3-antibody which 
granulosa did not attach to oocyte properly that leads to 
oocyte extrusion [6]. Paterson reported the exposure of 
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HZP3 recombinant in Marmoset, caused disturbance of 
folliculogenesis and decreased primordial follicle [7]. In 
contrary, Mustofa found that there were no abnormality 
of ovary and follicles found after treatment of goat ZP3 
(gZP3) to the number of primordial, primary, second-
ary, and De Graff follicles [5]. A similar finding was also 
reported by Bagavant et al., that Macaca with three-fold 
immunization of porcine pellucid zone showed normal 
ovulation and follicle development [8]. 
The administration of ZP antibody affects the struc-
ture of zona pellucida and folliculogenesis. It also dis-
rupts gap junction among granulosa cells and oocyte 
leading to disturbance of follicle development which will 
be smaller than normal. Disturbance of gap junction be-
tween oocyte and granulosa cells causes Premature 
Ovarium Failure (POF) [6]. 
Follicles viability is determined by its diameter 
where 2 – 5 mm is considered normal and healthy. It 
further developed into dominant follicles of 5 – 18 mm 
and then ovulated. If selected follicles change to non-
dominant follicles sized 0.5 – 10 mm, follicles will un-
dergo atresia via apoptosis [9, 10]. Both follicles growth 
and atresia involve Bcl-2 protein which is responsible for 
viability and apoptosis of granulosa cells. 
The Bcl-2 family consisted of anti-apoptosis (Bcl-2 
and Bcl-x) and pro-apoptosis (Bax and Bid), involved in 
regulating apoptosis on the intrinsic pathway, by pro-
moting cytochrome C release in mitochondria. In Bcl-2-
deficient mice, oocyte and primordial follicles reduced. 
The increased Bcl-2 can reduce apoptosis of granulosa 
cells during folliculogenesis. Bax is highly expressed in 
granulosa cells of follicles which undergo atresia, com-
pared to healthy follicles in human [11]. 
Development of immunocontraception of pellucid 
zone among mammals, both native and recombinant, is 
widely developed from cows, goats, or rabbits. It shows 
the interspecific reaction of antibody on ZP3 [4]. Mu-
barakati et al. produced ZP3 antibody from human 
blood (mab-hZP3) as a potential candidate for immuno-
contraception, but its side effect on folliculogenesis still 
need to be further studied [12]. Thus, this study aimed 
to determine side effects of monoclonal antibody on fol-
liculogenesis, specifically on the expression level of Bcl-
2 and Bax. 
 
MATERIALS AND METHOD 
Research design and animal model 
The research design used was a true experiment 
using Post Only Control Group Design approach. The 
study was conducted in Animal Model Unit Laboratory, 
Faculty of Medicine, Airlangga University, Surabaya, 
Indonesia. Forty-eight female BALB/c mice (Mus mus-
culus) were divided into 12 groups of experimental treat-
ment (3 mice of each group). Each group was added by 
30% (1 mice) of total mice required as error sample. 
Groups were then divided into 3 control groups and 9 
experiment group. The independent variables were hu-
man pellucid zone-3 monoclonal antibodies in various 
doses and time, and dependent variable were Bcl-2 and 
Bax expression of follicle granulosa in mice ovary. 
 
Treatment of adjuvant and Mab hZP3 
The control mice groups were injected subcutan-
eously in back feet with a syringe containing adjuvant of 
20 µL. The experiment groups mice were also injected 
subcutaneously with hZP3 monoclonal antibody in 
AI(OH)3 (Alumina Hydrogel) by various doses of 20 µg, 
40 µg, and 60 µg. 
According to Ma et al., and Dahlberg et al., anti-
body injected into the subcutaneous region or intramus-
cular way, was absorbed through lymphatic tissue. Ab-
sorption takes 2 – 8 days to peak its plasma concentra-
tion (t-max) with bioavailability between 50 – 100% [13, 
14]. 
 
Analysis histopathology of the ovary 
Histopathology visualization of the ovary was per-
formed with fixation with Paraformaldehyde (PFA) 
10%. Afterward, the organ was dehydrated, cleared, im-
pregnated, and embedded. Organ cutting and staining 
were performed immunohistochemically. 
 
Measurement of Bcl-2 and Bax expression 
Measurement of Bcl-2 and Bax expression in gran-
ulosa cells was performed immunohistochemically ac-
cording to BIOSS protocol. 
 
Statistical analysis 
Data analysis was Two-Way ANOVA with conf-
ident level 95%. This aimed to compare mean among 
groups (control and experimental treatments) in various 
doses and time. Data obtained from Bcl-2 and Bax meas-
urement was tabulated based on groups and analyzed 
statistically. The dataset was previously tested its para-
metric condition. 
 
RESULTS AND DISCUSSION 
Measurement of Bcl-2 and Bax expression 
Vaginal swab during estrus period in mice is shown 
in Figure 1. The histopathology visualization was shown  
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Figure 1. Vaginal swab on estrus cycle: (A) proestrus; (B) estrus; (C) metestrus; (D) diestrus. Visualization of Bcl-2 expression in 
secondary follicle granulosa: (E) there was no Bcl-2 expression in secondary follicle granulosa; F) expression of Bcl-2 in 
granulosa indicated by chromogen brown (white arrow) in granulosa (400×). (G) Bax visualization in secondary follicle 
granulosa, Red arrow shows there was no Bax expression in secondary follicle granulosa and blue arrow shows Bax ex-
pression in granulosa indicated by brown chromogen in granulosa 
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with light Nikon H600L facilitated by digital camera DS 
Fi2 300 megapixel and image processing software, Nik-
kon Image System to measure Bcl-2 and Bax expression. 
Visualization of Bcl-2 expression in secondary follicle 
granulosa is shown in Figure 1. 
The measurement of Bcl-2 and Bax expression in 
various doses and time was analyzed with ANOVA. As 
shown in Table 1, p-value on Bcl-2 and Bax expression 
was more than α = 0.05. Those results explained that 
data variable of Bcl-2 and Bax expression was distributed 
normally. Homogeneity test was conducted with Levene 
test (p > 0.05)  
p-value on Bcl-2 expression was more than α = 0.05 
(p > 0.05) which indicates variable of Bcl-2 expression 
was homogeneous (Table 1). p-value of Bax expression 
was less than α = 0.05 (p < 0.05). Therefore, data trans-
formation was further required. Logarithm transfor-
mation was used by converting data to the logarithm 
(Log (10Y)). In variable of Bax, there was observation 
measured as 0 (Y=0), thus, the transformation was fur-
ther performed log transformation Log (10(Y+0.5)). 
These are results of homogeneity test transformed. Bax 
expression variable is shown in Table 3. p-value < 0.05 
indicates variable was not homogeneous even after 
through log transformation. Thus, the test was per-
formed non-parametric by transforming data with Rank 
Transform method and further analyzed with ANOVA. 
Bax expression has coefficient 2.957 with p-value 0.007 
and it assumes that not homogenous. 
 
Effect of Mab-hZP3 in various doses on Bcl-2 and Bax 
expression 
ANOVA analysis showed p-value was 0.825, higher 
than α = 0.05 (p > 0.05) which concluded there was no 
significant effect of Mab-hZP3 on Bcl-2 expression. Ef-
fect of mab-hZP3 in various doses is shown in Figure 
2(a). As shown in the histogram, an average of Bcl-2 
expression was highest in the control group. It was 
presented that Bcl-2 level decreased due to the admin-
istration of Mab-hZP3 in various doses. However, the 
effect of Mab-hZP3 on Bcl-2 expression was not statisti-
cally significant. 
Effect of Mab-hZP3 in various doses on Bax expres-
sion was also analyzed with ANOVA. ANOVA results 
showed p-value was 0.505 (p > 0.05), which concluded 
there was no significant effect of Mab-hZP3 on Bax ex-
pression. The effect of Mab-hZP3 in various doses is 
shown in Figure 2(d). As shown in the histogram, an 
average of Bax expression is lowest in the control group. 
It was also found increasing Bax level in the administra- 
tion of Mab-hZP3 in various doses, although it was not 
significant. 
Results showed Bcl-2 expression in the treatment 
group was lower than control, whereas Bax expression 
was higher in the treatment group than control, alt-
hough statistically, effect of Mab-hZP3 was not signifi-
cant. 
Decreased Bcl-2 and increased Bax occurs due to 
Mab-hZP3 administration disturbs cells where Bcl-2 and 
Bax expressed. Borillo et al. [15] stated that the admin-
istration of ZP3 causes disturbance of ovarium for-
mation [15]. ZP3 administration on preantral follicles 
will disrupt ZP3 protein synthesis and secretion. In mi-
croscopic observation, ZP seems thin, transparent, 
loosen, swollen, and half dissolved, and slot emerged be-
tween ZP-oocyte, ZP-granulosa cell, and among granu-
losa cells. The slot formed due to F171 dysfunction af-
fecting gap junction formation which decreases the 
amount of gap junction between oocyte and granulosa.  
In vitro study of Calongos et al., found that 
preantral follicles cultured with ZP2/ZP3-antibody did 
not develop to antral follicles on day 4, and granulosa 
differentiation and antrum were also absent [6]. Results 
of day 7 showed incomplete follicles development and 
granulosa attachment to the oocyte, causing oocyte ex-
traction and granulosa degeneration.  
In Bcl-2-deficient mice, decreased oocyte and pri-
mordial follicles are present due to the low level of Bcl-
2 which is responsible reducing apoptosis in granulosa, 
whereas a high level of Bax is present in granulosa of 
follicles which undergo atresia [11]. In contrary, 
Mustofa observed the effect of gZP3 antibody in various 
doses of 20 µg and 40 µg in two treatment groups and 
results showed there was no disturbance of follicles in 
mice ovary and abnormality of ovarium [5]. Study of 
East et al., showed mZP3 monoclonal antibody in mi-
crogram quantity both in vitro and in vivo, inhibits fer-
tilization and also has no effect on follicle and embryo 
development [16, 17]. Study of Bagavant et al., also re-
ported pZP3 immunization on monkey has no effect on 
decreasing follicle and increasing atresia follicles [18]. 
 
Effect of Mab-hZP3 at various times on Bcl-2 and Bax 
expression 
The effect of Mab-hZP3 at various times on Bcl-2 
expression was analyzed with ANOVA. Analysis of 
ANOVA obtained the p-value equal to 0.807 (p > 0.05), 
which considered there was no significant effect on the 
administration of Mab-hZP3 at various time on Bcl-2 
expression. The effect of Mab-hZP3 at various times is  
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Figure 2.  Effect of Mab-hZP3 in (A) various doses, (B) various time and in (C) various doses and time on BCL-2 expression. Effect 
of Mab-hZP3 in (D) various doses, (E) various time and in (F) various doses and time on Bax expression (P1 = Mab-hZP3 
20 µg, P2 = Mab-hZP3 40 µg, and P3 = Mab-hZP3 60 µg). Data are mean of ± standard deviation values of three mice in 
each group with p-value <0.05. Different letters indicate significant difference based on Tukey’s high significant differences 
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shown in Figure 2(b). As shown in Figure 2(b), the high-
est average of Bcl-2 expression was 2.09 found on day 
10. Furthermore, decreasing Bcl-2 level occurred on day 
15 and 20. Decreased Bcl-2 at its lowest level was ob-
tained on day 15, although it was not significant.  
Effect of Mab-hZP3 at various times on Bax expres-
sion analyzed with ANOVA is shown in Figure 2(e). 
ANOVA results showed that p-value equal to 0.031 
(p<0.05), which considered to have significant effect in 
various time on Bax expression. As shown in Figure 2, 
the lowest average of Bax expression was 4.88 in day 10 
followed by increasing its level in day 15 and 20. The 
highest increasing level of Bax is on day 20 which con-
sidered significant compared to day 10.  
If administration time is associated with the effect 
of a compound including immunoglobulin (antibody), a 
monoclonal antibody can reach to 20 days of its effec-
tiveness. According to Keizer, IgG is a big molecule 
since it is not carried out through urine [19]. Longest 
IgG period is 21 days. 
After the antibody injection, the immune system 
will immediately react after injection and held during 
IgG lifetime in vivo which is approximately 3 week [20]. 
Results showed that Bcl-2 decreased on day 15 (com-
pared to day 10 and 20) due to the presence of Mab-
hZP3, whereas Bax level increased in various doses. The 
results obtained due to the disturbance of granulosa cells 
as a result of altered ZP caused by a monoclonal anti-
body. Decreased Bcl-2 in day 15 might be associated 
with monoclonal antibody absorption temporarily, fol-
lowing its increasing in day 20. The part of the pellucid 
zone can be found in granulosa intercellular space, 
therefore, ZP antibody affects granulosa.  
Granulosa maintains follicles viability [11, 21]. Bcl-
2 and Bax are expressed as antiapoptosis and proapop-
tosis in granulosa cell. The role of Bcl-2 as anti-apoptosis 
is to bind and neutralize proapoptotic protein granulosa. 
Otherwise, Bax as proapoptotic promotes apoptosis in 
granulosa cell. Low level of Bcl-2 generates atresia on 
follicle preceded by apoptosis [22, 23]. 
Expression of Bcl-2 and Bax are also associated with 
gonadotropin level which increasing gonadotropin and 
Bcl-2 but decreasing Bax otherwise [24]. Statistically, 
there was no difference in the effect of Mab-hZP3 in 
various time on Bcl-2 and Bax due to the monoclonal 
antibody as a compound of immunocontraception. Mo-
noclonal antibody is known specific and directly acts on 
a targeted cell, ZP3; it has only one epitope to recognize 
a specific antigen. Its specificity affects the role of ZP3 
as a primary receptor on spermatozoa recognizing [25]. 
Effect of Mab-hZP3 in various doses and time on Bcl-2 
and Bax expression 
The effect of Mab-hZP3 in various doses and time 
on Bcl-2 expression was analyzed with ANOVA (Figure 
2(f)) . Analysis of ANOVA showed the p-value was 
0.088 (p > 0.05) which concluded there was no signifi-
cant effect of interaction between Mab-hZP3 in various 
doses and time on Bcl-2 expression. As shown in the 
histogram, an average of Bcl-2 expression in the control 
group was relatively similar to the treatment group of 
Mab-hZP3 in various doses. Decreased Bcl-2 at its low-
est level occurred in the administration of a Mab-hZP3 
dose of 60 µg (P3) in day 15, although it was not signif-
icant. 
The effect of Mab-hZP3 in various doses and time 
on Bax expression analyzed with ANOVA is shown in 
Figure 2(c). ANOVA results showed p-value was 0.098 
(p > 0.05), which considered that there was no signifi-
cant effect of interaction between Mab-hZP3 in various 
doses and time on Bax expression. As shown in the his-
togram, an average of Bax expression was highest in the 
control group on day 20. Increasing Bax level in the 
treatment group was on a dose of 60 µg (P3) in day 20 
although it was not significant. 
Statistical analysis showed the administration of 
Mab-hZP3 in various time and time has no significant 
change in Bcl-2 and Bax expression due to the high spec-
ificity of Mab-hZP3. Human ZP3 monoclonal antibody 
causes damage of ZP loci. Monoclonal antibody directly 
acts on ZP3 and effects on the ZP3 role as a primary 
receptor for sperm recognition. Human ZP3 as another 
monoclonal antibody is specific, has one epitope to only 
identify specific antigen [25]. Bukovsky et al. reported 
murine Mabs-ZP3 monoclonal antibody has high speci-
ficity on human ZP3 protein [26]. There is no cross-
reactivity Mabs-mZP3 found in the ovary and other tis-
sues such as endometrium, uterus, cervix, tuba falopii 
and kidney. 
Study of Sumitro et al., performed with Western 
Blot, showed that Mab-bZP3 recognizes bZP3 on mole-
cule weight of 79,995±0.051 kDa indicating Mab-bZP3 
recognize bZP3 rather than other molecules [27]. It con-
cludes that Mab-hZP3 only recognize ZP3 as a primary 
receptor of sperm recognition without affecting repro-
duction organ and folliculogenesis. 
The administration of polyclonal antibodies to pZP 
in in-vitro studies using eggs and human spermatozoa 
has been shown to cause inactivation of spermatozoa re-
ceptor sites by interaction with epitope or interaction 
with sites around spermatozoa receptors. This led to the  
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prevention of spermatozoa and egg ties up to 95%. The 
administration of antibodies to pZP3α in intact ZP was 
significantly capable of inhibiting spermatozoa and egg 
[28]. The bonding of ZP antibodies with ZP can cause 
conformational changes and epitope surfaces. This 
change is similar to ZP-shaped changes in the fertiliza-
tion process and zone blocking which can lead to prem-
ature induction of cortical granular reactions resulting 
in ZP hardened, and infertile [29]. The HZP3 monoclo-
nal antibody works directly on target cells, giving ZP3 
antibodies in mice serum in-vivo causing changes in ZP 
structure in the early stages of antral follicle growth in 
the form of disruption of gap junction formation be-
tween oocytes and granulosa cells [30]. 
Apoptosis is a programmed cell death which is ge-
netically regulated and involves many physiology and 
pathology process. Signals activating apoptosis originate 
from reactive oxygen species (ROS), ceramide, excess 
Ca2+ activation, Bcl-2 protein family [28]. This member 
of Bcl-2 family consists of antiapoptosis, Bcl-2, and 
proapoptosis, Bax. The balance of Bcl-2 family is estab-
lished by controlling the amount of pro-apoptosis and 
anti-apoptosis which is simultaneously active. Activities 
such as DNA damage can interfere pro and anti-apop-
tosis balance which promotes programmed cell death 
[29]. Although the effect of Mab-hZP3 in various doses 
and time on Bcl-2 and Bax expression was not signifi-
cant statistically, decreasing Bcl-2 level was detected in 
the treatment group with the lowest peak on the dose of 
60 µg in day 15 whereas increasing Bax level was on a 
dose of 60 µg in day 20. Such results occurred due to 
atresia in follicle selection which only involves one dom-
inant follicle to ovulate. 
Follicle atresia includes apoptosis and granulosa re-
lease, oocyte autolysis, and pellucid zone collapse. Atre-
sia occurs in each stage of follicle development [30]. Ad-
ministration of Mab-hZP3 also affects ZP formation by 
causing depletion which is associated with oocyte gap 
junction, granulosa cells and two-way communication 
oocyte, granulosa that plays a role in folliculogenesis and 
oogenesis. Gap junction highly influences growth and 
development of oocyte and granulosa. ZP antibody 
causes granulosa dysfunction as well [24, 31]. 
 
CONCLUSION 
In this study, administration of Mab-HZP3 in vari-
ous doses and time has no significant effect on Bcl-2 and 
Bax expression. Mab-HZP3 administration did not de-
crease Bcl-2 level and increasing Bax level significantly. 
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